

# Universal vaccines against respiratory pathogens

J B Davies<sup>1</sup>, M Alsharifi<sup>2,3</sup>, T Hirst<sup>3</sup>

<sup>1</sup> Australian Nuclear Science and Technology Organisation

<sup>2</sup> School of Biological Sciences, University of Adelaide

<sup>3</sup> Gamma Vaccines Pty. Ltd.



Australian Government

**Ansto**



THE UNIVERSITY  
of ADELAIDE



*gamma vaccines* pty limited

International Atomic Energy Agency Scientific Forum


**ATOMS IN INDUSTRY**

**Radiation Technology for Development**

15–16 September 2015, Vienna, Austria

# Gamma Irradiation at ANSTO

- Co-60 irradiator since 1970
- Very low (1 Gy) to High (> 50 kGy)
- Precision & Accuracy not achievable in industrial irradiation
- Research & Development underpins industrial radiation processing



# Dosimetry

- Precise irradiation is enabled by accurate Dosimetry
- Our dosimetry systems are traceable to the Australian Primary Standard for Absorbed Dose

Dosimeter	Dose range	Uncertainty (95% confidence)
Ionisation chambers	1 mGy to 10 Gy	0.7 %
Fricke	50-350 Gy	2.0 %
Low Dose Ceric Cerous	1-12 kGy	3.0 %
High Dose Ceric Cerous	10-50 kGy	3.5 %



# Radiation Sterilisation


Two effects on biological systems:

DIRECT EFFECTS:

- Direct interaction with nucleic acids (strand breakage)

INDIRECT EFFECTS

- generation of short-lived free radicals
- causes excess damage to structural components as well as nucleic acid
- HIGH temperature → increases indirect effects
- LOW temperature → reduces indirect effects and direct effects predominate (**PROTECTS PROTEINS**)



# Influenza A virus

**TYPES:** A, B and C


- Type A: (most prevalent) aquatic birds are natural hosts and transmit to humans

**TRANSMISSION:** airborne droplets

**SYMPTOMS:** Causes acute inflammation within the upper and lower respiratory tracts

- headache, fever, runny nose, sore throat, coughing

**OUTCOME:** Causes more than 250,000 deaths annually (elderly and young children more susceptible to disease)




# Epidemiology



Year	Flu	Deaths worldwide
1918/1919	Spanish influenza (H1N1)	50 million
1957	Asian influenza (H2N2)	4 million
1968/1969	Hong Kong influenza (H3N2)	4 million
2009	Swine Flu (H1N1)	200,000



# Current Inactivated Vaccines



# The composition of influenza A virus vaccines for use in Southern Hemisphere influenza seasons recommended by the WHO were:

2006 Season
<ul style="list-style-type: none"><li>• an A/New Caledonia/20/99 (H1N1)-like virus</li><li>• an A/California/7/2004 (H3N2)-like virus</li></ul>
2007 Season
<ul style="list-style-type: none"><li>• an A/New Caledonia/20/99 (H1N1)-like virus</li><li>• an A/Wisconsin/67/2005 (H3N2)-like virus</li></ul>
2008 Season
<ul style="list-style-type: none"><li>• an A/Solomon Islands/3/2006 (H1N1)-like virus</li><li>• an A/Brisbane/10/2007 (H3N2)-like virus</li></ul>
2009 Season
<ul style="list-style-type: none"><li>• an A/Brisbane/59/2007 (H1N1)-like virus</li><li>• an A/Brisbane/10/2007 (H3N2)-like virus</li></ul> <p><i>Pandemic H1N1 virus was not part of Flu vaccine composition for 2009 season</i></p>
2010 Season
<ul style="list-style-type: none"><li>• an A/California/7/2009 (H1N1)-like virus</li><li>• an A/Perth/16/2009 (H3N2)-like virus</li></ul>



www.nature.com



www.jhsph.edu



Thus: we are playing a catch up game with influenza virus!

# Current Flu vaccines: Strain specific vaccines

What is the alternative:

## **Cross-reactive T-cell based vaccine**


- Irradiation to inactivate influenza viruses to create more effective vaccines
- Adelaide University with Gamma Vaccines research to validate commercial product

## Gamma-irradiated influenza A virus vaccine




# Transmission electron microscopy

A/California/07/2009 H1N1



Gamma-irradiated H1N1



**Shannon David**

PhD student

The University of Adelaide



Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations


Yoichi Furuya,<sup>1</sup> Matthias Regner,<sup>1</sup> Mario Lobigs,<sup>2</sup> Aulikki Koskinen,<sup>1</sup> Arno Müllbacher<sup>1</sup> and Mohammed Alsharifi<sup>1</sup>

Correspondence  
Arno Müllbacher  
arno.mullbacher@anu.edu.au  
Mohammed Alsharifi  
mohammed.alsharifi@imvssa.gov.au

<sup>1</sup>Viral Immunology and Molecular Virology, The John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia

<sup>2</sup>Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

A: Homologous challenge with A/PC



Homotypic challenge with H3N2 (A/PC)

I.N Vaccination	Protection
Formalin-H3N2	NO
UV-H3N2	NO
<b>γ-H3N2</b>	<b>Yes</b>



Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations


Yoichi Furuya,<sup>1</sup> Matthias Regner,<sup>1</sup> Mario Lobigs,<sup>2</sup> Aulikki Koskinen,<sup>1</sup> Arno Müllbacher<sup>1</sup> and Mohammed Alsharifi<sup>1</sup>

Correspondence  
Arno Müllbacher  
arno.mullbacher@anu.edu.au  
Mohammed Alsharifi  
mohammed.alsharifi@imvssa.gov.au

<sup>1</sup>Viral Immunology and Molecular Virology, The John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia

<sup>2</sup>Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

B: Heterosubtypic challenge with A/PR8



Heterosubtypic challenge with H1N1 (A/PR8)

I.N Vaccination	Protection
Formalin-H3N2	NO
UV-H3N2	NO
γ-H3N2	Yes




## Cytotoxic T Cells Are the Predominant Players Providing Cross-Protective Immunity Induced by $\gamma$ -Irradiated Influenza A Viruses<sup>∇</sup>

Yoichi Furuya,<sup>1</sup> Jennifer Chan,<sup>2</sup> Matthias Regner,<sup>1</sup> Mario Lobigs,<sup>3</sup> Aulikki Koskinen,<sup>1</sup> Tuckweng Kok,<sup>2</sup> Jim Manavis,<sup>2</sup> Peng Li,<sup>2</sup> Arno Müllbacher,<sup>1\*</sup> and Mohammed Alsharifi<sup>1,2\*</sup>

*Viral Immunology*<sup>1</sup> and *Molecular Virology*,<sup>3</sup> *The John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia*, and *Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia*<sup>2</sup>

Vaccination with  $\gamma$ -H3N2  
Challenged with H1N1




**Early clearance of influenza virus from the lung of vaccinated animals**




## Cytotoxic T Cells Are the Predominant Players Providing Cross-Protective Immunity Induced by $\gamma$ -Irradiated Influenza A Viruses<sup>∇</sup>

Yoichi Furuya,<sup>1</sup> Jennifer Chan,<sup>2</sup> Matthias Regner,<sup>1</sup> Mario Lobigs,<sup>3</sup> Aulikki Koskinen,<sup>1</sup> Tuckweng Kok,<sup>2</sup> Jim Manavis,<sup>2</sup> Peng Li,<sup>2</sup> Arno Müllbacher,<sup>1\*</sup> and Mohammed Alsharifi<sup>1,2\*</sup>

*Viral Immunology*<sup>1</sup> and *Molecular Virology*,<sup>3</sup> *The John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia*, and *Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia*<sup>2</sup>



**Early T-cell responses in the lung of vaccinated animals**



**Thank you!**



**Australian Government**

**ansto**